Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.15
Bid: 7.80
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 0.70 (8.974%)
Open: 8.15
High: 8.15
Low: 8.15
Prev. Close: 8.15
TEK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Belluscura raises £750,000 of additional funding

6 Aug 2019 07:00

RNS Number : 9743H
Tekcapital plc
06 August 2019
 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

6 August 2019

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")

Portfolio Company Update

Belluscura Raises a further £750,000 in its latest fundraising round

 

Tekcapital Plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, is pleased to announce that its portfolio company Belluscura plc has raised £750,000 of additional funding. The funds will be used to complete regulatory clearance and launch its innovative X-PLOR portable oxygen concentrator. This brings the total amount raised by Belluscura in 2019 to £2.15m.

 

The Product

Belluscura has developed a patented portable oxygen concentrator called the X-PLOR, that can deliver 96% pure oxygen to patients 24/7. According to the Company1, the X-PLOR is designed to replace metal oxygen tanks and heavier devices. Weighing only 1.4kg, X-PLOR is 33% lighter and research suggests can provide 37% more oxygen per kg than leading competitors. X-PLOR is portable, increasing the mobility of people suffering from COPD and price efficient, costing less than tanks over the duration of the disease, and is upgradeable with user replaceable filters, so as the disease progresses, there is no need to buy another expensive higher capacity device, rather just change the filter as the prescription changes. Belluscura has exclusively licensed, acquired or filed 13 patents and applications in the field of concentrated oxygen generation and has a robust pipeline with additional oxygen enrichment products planned for release in 2020.

 

Market Information

Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease. Over 250 million people worldwide suffer from COPD2. COPD is not curable, but patients with COPD are prescribed supplemental oxygen to help relieve shortness of breath and reduce the risk of death. According to the British Lung Foundation, in the U.K. an estimated 1.2 million people are living with diagnosed COPD.3 Globally, the medical portable O2 concentrator market is expected to grow from $1.4bn in 2018 to $2.4bn by 2024, with a CAGR of 9%.4

 

Dr Clifford Gross, Chairman at Tekcapital commented,

"We are delighted to see that Belluscura has further strengthened its balance sheet. The fundraise was conducted at 15p per share, a 50% uplift over the valuation Tekcapital listed for Belluscura in its 2018 Annual Accounts. The Directors believe that Belluscura's new device will help to improve the quality of life and reduce treatment cost for individuals suffering from COPD."

 

Tekcapital owns approximately 19.2% (9.3m shares) of Belluscura plc.

 

About Belluscura plc

Belluscura plc is an English company that is focused on improving healthcare and people's lives by developing new and innovative treatment platforms. They license and develop proprietary technologies that can be applied across a range of treatment possibilities. To learn more please visit www.belluscura.com.

 

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed intellectual properties and provides a range of IP investment services to make it easy for organisations to commercialise university-developed technology. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

LEI: 213800GOJTOV19FIFZ85

 

 

For further information, please contact:

Tekcapital Plc 

Via Yellow Jersey PR 

Clifford M. Gross, Ph.D. 

 

 

 

finnCap Ltd (Nominated Adviser and Joint Broker)

+44 (0) 20 7220 0500 

Geoff Nash/ Max Bullen-Smith (Corporate Finance)

 

Camille Gochez (ECM) 

 

Novum Securities Limited (Joint Broker) 

+44 (0) 20 7399 9427

Colin Rowbury (Corporate Broking) 

 

 

 

Yellow Jersey Limited

+44 (0) 20 7933 8780 

Tim Thompson / Annabel Atkins 

tekcapital@yellowjerseypr.com 

 

 

 

 

References

1 https://www.belluscura.com/product-pipeline/

2 https://www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

3 https://statistics.blf.org.uk/copd

4 https://www.gminsights.com/industry-analysis/medical-oxygen-concentrators-market-report

 

This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Belluscura or Tekcapital that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Belluscura or Tekcapital's management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Belluscura or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither Belluscura nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKPDQCBKDKFK
Date   Source Headline
26th Jan 20173:00 pmRNSResults of proposed placing to raise £2.4m
26th Jan 20177:00 amRNSProposed placing
12th Jan 20177:00 amRNSNotice of Allowance for Energy Harvester Patent
4th Jan 20177:00 amRNSSuccessful Production and Testing of µSaltTM
28th Dec 20167:00 amRNSOut-licence & Strategic Alliance with Wecast
9th Nov 20167:00 amRNSDirectorate Change
31st Oct 20167:00 amRNSStrategic Alliance with Bajainnova SAPI de CV
28th Oct 20167:00 amRNSNotice of Allowance for 2nd Crackle-baked Patent
25th Oct 20167:00 amRNSPrivate Placement for Belluscura Ltd
7th Oct 20164:28 pmRNSHolding(s) in Company
15th Sep 20167:00 amRNSAcquisition of Medical Device Licence
31st Aug 20167:00 amRNSHalf-year Report
30th Jun 20167:30 amRNSGrant of Options
17th Jun 20167:00 amRNSPrivate Placement for Belluscura Ltd
6th Jun 201611:44 amRNSAcquisition of salt reduction technology patent
27th May 20162:47 pmRNSResult of AGM
4th May 20167:00 amRNSPosting of Annual Report and Notice of AGM
29th Apr 20167:00 amRNSFinal Results
28th Apr 20167:00 amRNSAcquisition and Total Voting Rights
20th Apr 201612:53 pmRNSHolding(s) in Company
13th Apr 20167:00 amRNSAcquisition of Medical Devices
14th Mar 20167:00 amRNSNew Technology License
12th Feb 20167:00 amRNSDirectorate Change
12th Jan 20167:00 amRNSTekcapital Chairman announced as award finalist
4th Jan 20163:06 pmRNSHolding(s) in Company
24th Dec 20157:00 amRNSAcquisition of Energy Harvesting Technology
22nd Dec 201512:52 pmRNSHolding(s) in Company
30th Nov 20155:30 pmRNSTotal Voting Rights
24th Nov 20152:14 pmRNSExercise of warrants and total voting rights
23rd Nov 20157:00 amRNSPatent Update for Crackle-baked(R) Technology
13th Nov 20159:15 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSDirectorate Change
9th Nov 20157:00 amRNSNew Patent Application
9th Oct 20157:00 amRNSHolding(s) in Company
28th Aug 20155:00 pmRNSTotal Voting Rights
20th Aug 20157:00 amRNSHalf Yearly Report
14th Aug 20157:00 amRNSAcquisition of air conditioning efficiency patents
29th Jun 20157:00 amRNSAcquisition of energy harvesting technologies
22nd Jun 20154:27 pmRNSHolding(s) in Company
12th Jun 201511:52 amRNSResult of General Meeting
8th Jun 20157:00 amRNSGrant of Share Options
29th May 20156:15 pmRNSHolding(s) in Company
29th May 20156:15 pmRNSTotal Voting Rights
29th May 20151:13 pmRNSResult of AGM
21st May 201512:52 pmRNSFinal Results
14th May 20154:07 pmRNSHolding(s) in Company
13th May 20157:00 amRNSHolding(s) in Company
12th May 20152:00 pmRNSHolding(s) in Company
12th May 20157:00 amRNSHolding in Company and Directorate Change
6th May 20152:46 pmRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.